Development of novel cannabinoid CB1receptor antagonists with high oral absorption and no central adverse effects for the treatment of cardiovascular diseases
Using high-throughput screening, we discovered that soybean isoflavone genistein (GEN) is a novel CB1 receptor antagonist that does not cross the blood-brain barrier, thereby avoiding CNS effects and psychiatric side effects. We further enhanced the water solubility and oral bioavailability of GEN through microbial fermentation. This strategy has been patented and can be used to treat cardiovascular diseases and has therapeutic potential for other diseases related to abnormal CB1 activation.
A deep learning-powered novel artificial intelligence algorithm and syste m to assist in the identification of pneumoperitoneum on abdominal com puted tomography
Development of an Implantable Bioelectronic Platform for the Peripheral Neuromuscular System Regeneration
Platform for Oligonucleotide Drug Production (Nucleic Acid Drugs for the Treatment of Pulmonary Fibrosis)
Application of a novel nucleic acid structure immune activation composition as adjuvant for nasal spray vaccines
Technology maturity：Prototype
Exhibiting purpose：Display of scientific results
Trading preferences：Negotiate by self
Coming soon!